QCG
CYTK icon

Quadrant Capital Group’s Cytokinetics CYTK Stock Holding History

Quadrant Capital Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
15,533
+167
+1% +$12K 0.04% 467
2026
Q1 		$1.01M Buy
15,366
+670
+5% +$42.6K 0.03% 562
2025
Q4 		$934K Buy
14,696
+5,448
+59% +$339K 0.03% 592
2025
Q3 		$508K Buy
+9,248
New +$381K 0.02% 868
2025
Q2 		– Sell
-11,013
Closed -$443K – 1661
2025
Q1 		$443K Buy
11,013
+7,330
+199% +$337K 0.02% 821
2024
Q4 		$173K Buy
3,683
+31
+0.8% +$1.61K 0.01% 763
2024
Q3 		$193K Buy
3,652
+271
+8% +$15.1K 0.01% 716
2024
Q2 		$183K Sell
3,381
-668
-16% -$40.3K 0.01% 695
2024
Q1 		$284K Buy
4,049
+781
+24% +$60.4K 0.02% 489
2023
Q4 		$273K Buy
3,268
+287
+10% +$10.4K 0.02% 478
2023
Q3 		$87.8K Buy
2,981
+1,330
+81% +$44.3K 0.01% 952
2023
Q2 		$53.9K Buy
1,651
+147
+10% +$5.44K 0.01% 1222
2023
Q1 		$52.9K Sell
1,504
-628
-29% -$25.6K 0.01% 1205
2022
Q4 		$97.7K Buy
2,132
+173
+9% +$7.44K 0.01% 784
2022
Q3 		$95K Buy
1,959
+1,596
+440% +$76.8K 0.01% 719
2022
Q2 		$14K Buy
363
+233
+179% +$9.38K ﹤0.01% 1467
2022
Q1 		$5K Buy
130
+63
+94% +$2.24K ﹤0.01% 1899
2021
Q4 		$3K Hold
67
– – ﹤0.01% 2017
2021
Q3 		$2K Buy
67
+10
+18% +$294 ﹤0.01% 2119
2021
Q2 		$1K Hold
57
– – ﹤0.01% 2240
2021
Q1 		$1K Hold
57
– – ﹤0.01% 2198
2020
Q4 		$1K Sell
57
-6
-10% -$110 ﹤0.01% 2083
2020
Q3 		$1K Buy
63
+6
+11% +$140 ﹤0.01% 1946
2020
Q2 		$1K Buy
+57
New +$1.07K ﹤0.01% 2029

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrant Capital Group's CYTK Position: Q2 2026 in Review

Quadrant Capital Group increased its Cytokinetics (CYTK) stake by 1.1% in Q2 2026, buying an estimated $12K and bringing the position to 15,533 shares worth $1.32M. The position accounts for 0.04% of the portfolio, ranked #467.

Quadrant Capital Group first reported a position in CYTK in Q2 2020 and has held it in 24 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Quadrant Capital Group held 15,533 shares of Cytokinetics worth $1.32M as of Q2 2026.
  • Quadrant Capital Group bought 167 Cytokinetics shares in Q2 2026, an estimated $12K.
  • Cytokinetics made up 0.04% of Quadrant Capital Group's portfolio in Q2 2026, its #467 holding.
  • Quadrant Capital Group first reported a position in Cytokinetics in Q2 2020 and has held it in 24 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.